MIR493

Summary

MIR493 (microRNA 493, HGNC:32082) is a microRNA gene on chromosome 14q32.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574450 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32082
Approved symbol	MIR493
Name	microRNA 493
Location	14q32.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-493
Ensembl gene	ENSG00000207989
Ensembl biotype	miRNA
Entrez	574450
RNAcentral	URS000075C9D6 — miRNA, 89 nt, 25 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385254

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385254 — 1 exons

Exon	Start	End
ENSE00001500260	100869060	100869148

Expression profiles

Bgee: expression breadth broad, 71 present calls, max score 86.22.

Top tissues by expression

71 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	86.22	gold quality
sural nerve	UBERON:0015488	83.91	gold quality
blood	UBERON:0000178	83.01	gold quality
monocyte	CL:0000576	78.92	gold quality
fundus of stomach	UBERON:0001160	78.49	gold quality
muscle of leg	UBERON:0001383	78.05	gold quality
calcaneal tendon	UBERON:0003701	77.60	gold quality
gastrocnemius	UBERON:0001388	77.31	gold quality
right adrenal gland cortex	UBERON:0035827	75.09	gold quality
placenta	UBERON:0001987	74.45	gold quality
right adrenal gland	UBERON:0001233	74.21	gold quality
body of pancreas	UBERON:0001150	74.16	gold quality
stomach	UBERON:0000945	73.32	gold quality
lung	UBERON:0002048	72.78	gold quality
heart left ventricle	UBERON:0002084	71.48	gold quality
heart	UBERON:0000948	70.82	gold quality
colon	UBERON:0001155	70.26	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.12	gold quality
endometrium	UBERON:0001295	69.85	gold quality
left adrenal gland	UBERON:0001234	69.66	gold quality
left ovary	UBERON:0002119	69.52	gold quality
omental fat pad	UBERON:0010414	68.99	gold quality
right atrium auricular region	UBERON:0006631	68.97	gold quality
Ammon’s horn	UBERON:0001954	68.69	gold quality
body of stomach	UBERON:0001161	68.59	gold quality
ascending aorta	UBERON:0001496	68.23	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.97	gold quality
left adrenal gland cortex	UBERON:0035825	67.91	gold quality
thoracic aorta	UBERON:0001515	67.89	gold quality
transverse colon	UBERON:0001157	67.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.31

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• MiRNA-493 was up-regulated in pituitary carcinomas compared to ACTH adenomas (PMID:20960104)
• miR-493 is a new tumor suppressor miRNA in bladder cancer and inhibits cell motility through downregulation of RhoC and FZD4. (PMID:22057916)
• in a subset of colon cancer, upregulation of miR-493 during carcinogenesis prevents liver metastasis via the induction of cell death of metastasized cells. (PMID:22373578)
• MKK7 is a major functional target of miR-493, and its suppression thwarts liver metastasis of colon cancer cells. (PMID:24533778)
• High MIR493 expression is associated with invasion and chemo-resistance in gastric cancer. (PMID:26799283)
• The miR-493-5p/FUT4 pathway has therapeutic potential in breast cancer. (PMID:27375041)
• the existence of a dynamic negative feedback loop in the regulation of IGF1R and miR-493 mediated via Snail, is reported. (PMID:27956702)
• The mechanism of hepatocarcinogenesis and a promising blueprint for miR-493-5p-GP73 axis-oriented treatment of HCC. (PMID:28419971)
• these results demonstrated that miR-493 acts as a tumor suppressor and inhibits cell proliferation and cell cycle in human melanoma by directly targeting IRS4. (PMID:28475006)
• our findings firstly indicate that miR-493-5p levels may play an essential role in NSCLC progression by targeting oncogene ITGB1 suggesting that ITGB1 and miR-493-5p have potential prognostic value as tumor biomarkers in NSCLC patients. (PMID:28537888)
• Novel targets ANTXR1 and RSPO2 were confirmed to be suppressed by miR-493 directly. (PMID:28651234)
• Our results highlight that hyper-methylation of miR-493CpG island might play important roles in the development of lung cancer chemo-resistance by targeting TCRP1, which might be used as a potential therapeutic target in preventing the chemo-resistance of lung cancer. (PMID:28859669)
• MicroRNA 493-5p induced platinum/PARPinhibitor resistance exclusively in BRCA2-mutated carcinomas. (PMID:29617652)
• MiR-493 functioned as tumor suppressor in HCC cells by regulating ZFX expression. Thus, miR-493 may provide potential value for HCC treatment. (PMID:29758928)
• We proved the prognostic role of miR-493 in triple-negative breast cancer (PMID:29777630)
• results suggest that the miR-493-STMN-1 pathway contributes to hypoxia-induced tubular epithelial cell G2/M arrest and renal fibrosis (PMID:30183377)
• acted as a onco-miR in prostate cancer cells and promoted cell proliferation via inhibiting tumor suppresser PHLPP2 expression and activating Akt signaling pathway (PMID:30868840)
• High miR493 expression is associated with osteosarcoma. (PMID:31111286)
• miR-493-5p mediated part of its tumor-suppressor activity by abrogating overexpression of insulin-like growth factor 2 (IGF2) and the IGF2-derived intronic oncomir miR-483-3p in hepatocellular carcinoma cells characterized by IGF2 loss of imprinting. (PMID:31320614)
• Long noncoding RNA GAS6-AS2 sponges microRNA-493, thereby enhancing the malignant characteristics of breast cancer cells via upregulation of FUT4. (PMID:31839366)
• LINC01605 promotes the proliferation of laryngeal squamous cell carcinoma through targeting miR-493-3p. (PMID:31841192)
• MYCN expression levels were inversely correlated with miR-493-5p in tumor tissues. (PMID:31883160)
• MiR-493 Induces Cytotoxic Autophagy in Prostate Cancer Cells through Regulation on PHLPP2. (PMID:32188381)
• MicroRNA-493-5p suppresses colorectal cancer progression via the PI3K-Akt-FoxO3a signaling pathway. (PMID:32373957)
• Molecular Mechanisms and Therapeutic Potential of miR-493 in Cancer. (PMID:32422007)
• Lung cancerassociated transcript 1 facilitates tumorigenesis in laryngeal squamous cell carcinoma through the targeted inhibition of miR493. (PMID:33215214)
• Long non-coding RNA NR2F1-AS1 promoted neuroblastoma progression through miR-493-5p/TRIM2 axis. (PMID:33378023)
• miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development. (PMID:33793074)
• ILF3-AS1 promotes the aerobic glycolysis and proliferation of melanoma cells by regulating miR-493-5p/PDK1 pathway. (PMID:33913671)
• Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation. (PMID:34182091)
• MiR-493-5p inhibits the malignant development of gliomas via suppressing E2F3-mediated dysfunctions of P53 and PI3K/AKT pathways. (PMID:34460057)
• Long coding RNA CCAT2 enhances the proliferation and epithelial-mesenchymal transition of cervical carcinoma cells via the microRNA-493-5p/CREB1 axis. (PMID:34499007)
• Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. (PMID:34537072)
• Circular RNA circPRKDC promotes tumorigenesis of gastric cancer via modulating insulin receptor substrate 2 (IRS2) and mediating microRNA-493-5p. (PMID:34605348)
• SNHG1 functions as an oncogenic lncRNA and promotes osteosarcoma progression by up-regulating S100A6 via miR-493-5p. (PMID:35130629)
• Overexpression of miR-493-3p suppresses ovarian cancer cell proliferation, migration and invasion through downregulating DPY30. (PMID:35313261)
• Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis. (PMID:35761379)
• Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma. (PMID:36369960)
• LINC00324 promotes cell proliferation and metastasis of esophageal squamous cell carcinoma through sponging miR-493-5p via MAPK signaling pathway. (PMID:36493845)
• Propofol-Induced miR-493-3p Inhibits Growth and Invasion of Gastric Cancer through Suppression of DKK1-Mediated Wnt/beta-Catenin Signaling Activation. (PMID:36762306)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.